• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Sunovion Pharmaceuticals

spring cleaning clean scrub cleaning supplies wash sponge
Biotech

Sumitomo Pharma tidies up 7 units into one combined US entity

Sumitomo Pharma is doing a bit of spring cleaning to bring a handful of biopharma units under one consolidated company: Sumitomo Pharma America.
Annalee Armstrong Apr 3, 2023 12:16pm
behavioral health Mental health therapy

Researchers link genes to schizophrenia using trove of new data

Apr 6, 2022 11:26am
ax in a tree stump

Sunovion ditches once-rejected ADHD, binge eating program

May 13, 2020 11:20am
Blue purple pink 3d rendering of brain

Sunovion’s nondopamine schizophrenia drug hits phase 2 endpoint

Dec 13, 2018 10:06am
Cigarette smoke

Sunovion's COPD ambitions dented as FDA rejects phase 3 drug

May 30, 2017 8:23am
Toronto

Sunovion pays $624M for Cynapsus, PhIII Parkinson’s med

Sep 1, 2016 7:08am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings